跳至主要内容
临床试验/NCT04309175
NCT04309175Unknown不适用

Effect of Long-term Atrial Pacing on Central Blood Pressure in Permanently Paced Sick Sinus Syndrome Patients With Primary Arterial Hypertension

Tartu University Hospital0 个研究点目标入组 58 人开始时间: 2020年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
58
主要终点
systolic blood pressure amplification change

研究概览

简要总结

This is a randomized controlled single-centre clinical trial with a cross-over design to compare non-invasively evaluated central blood pressure and related parametres in sick sinus syndrome patients with hypertension who are paced long-term at a slower vs faster heart rate

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •age 18-80 years
  • •sick sinus syndrome
  • •permanent cardiac pacemaker with right atrial and right ventricular leads
  • •at least 3 months from implantation
  • •sinus rhythm
  • •percentage of atrial pacing at or above 80% since last interrogation
  • •percentage of ventricular pacing at or below 3% since last interrogation
  • •primary arterial hypertension
  • •antihypertensive drug treatment
  • •mean office brachial blood pressure below 140/90 mmHg
  • •mean home brachial blood pressure below 135/85 mmHg
  • •ability to understand and follow study protocol
  • •signed informed consent form

排除标准

  • •inclusion criteria not fulfilled
  • •violation of study protocol by subject, investigator or third part
  • •high quality central hemodynamic measurements cannot be perfomed
  • •inter-arm difference in brachial systolic blood pressure 15 mmHg or above
  • •intrinsic QRS complex 130 ms or above
  • •more than three antihypertensive agents in use
  • •treatment with digoxin or agents from Vaughan-Williams classes Ic, III või IV
  • •frequent high atrial rate episodes
  • •coronary artery disease
  • •secondary hypertension
  • •resistant hypertension
  • •orthostatic hypotension
  • •heart failure with decreased or preserved left ventricular ejection fraction
  • •implantable cardioverter-defibrillator or cardiac resynchronization therapy
  • •significant valvular heart disease
  • •significant congenital heart disease
  • •body mass index ≥35 kg/m2
  • •type I diabetes
  • •type II diabetes with cardiovascular complications or on insulin therapy
  • •other significant endocrine disease
  • •history of cerebrovascular attack
  • •carotid artery disease
  • •lower extremity arterial disease
  • •severe chronic obstructive pulmonary disease
  • •severe asthma
  • •severe sleep apnea
  • •interstitial pulmonary disease
  • •inhaled beta adrenergic agonist therapy
  • •active cancer treatment
  • •central nervous system degenerative disease
  • •systemic connective tissue disease
  • •abnormal TSH at present
  • •glomerular filtration rate ≤30 ml/min/m2
  • •hemoglobin <100 g/L (female), <110 g/L (male)
  • •hepatic dysfunction
  • •alcohol abuse
  • •pregnancy or breastfeeding
  • •no health insurance provided by Estonian Health Insurance Fund
  • •withdrawal of informed consent
  • •loss of contact with a subject during study

研究组 & 干预措施

Slow-Fast

Experimental

干预措施: base rate programming of a permanent cardiac pacemaker (Device)

Fast-Slow

Experimental

干预措施: base rate programming of a permanent cardiac pacemaker (Device)

结局指标

主要结局

systolic blood pressure amplification change

时间窗: two months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Tuuli Teeäär

cardiologist

Tartu University Hospital

相似试验